Cross-Sector entity
All 1 tracked stories fall under one category: market-trends. GLP-1 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. David Soergel appears in 1 tracked Cross-Sector story from February 24, 2026. The tracked stories average 5 original sources each.
1 verified story tracked
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. GLP-1 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. David Soergel appears in 1 tracked Cross-Sector story from February 24, 2026. The tracked stories average 5 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering David Soergel. Shared-story counts are live from our verified record — not editorial picks.
Payer Agreement Shift
New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
Q4 Milestone
Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
GLP-1 Strategic Acquisition
Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
Rezdiffra Full-Year Launch
Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.
Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
